Jiangsu Hengrui Medicine wins approval for phase 3 prostate cancer trial

Jiangsu Hengrui Medicine has received approval from the National Medical Products Administration (NMPA) to commence phase 3 clinical trials for its Relugolix Tablets for the treatment of prostate cancer. The drug, a second-generation AR inhibitor, is designed to offer stronger AR inhibition without agonistic effects compared to first-generation inhibitors. This approval follows the drug's initial market launch in 2022 for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).

The company's Relugolix Tablets project has accumulated approximately CNY 69,309m in research and development investment to date. According to EvaluatePharma data, similar products to Relugolix Tablets achieved combined global sales of approximately $110.37bn in 2024.

As with all drug development, Jiangsu Hengrui Medicine reminds investors that the process from clinical trial approval to market production is lengthy and subject to various uncertainties. The company will actively advance this research project and provide timely updates on its progress.